

4.0.03 DOC Cmte minutes

Colorectal Cancer (CRC) (update) Committee meeting 3

Date: 22nd February 2018

Location: RCOG, London

Minutes: Confirmed

Committee members present:		
Peter Hoskin, Chair (PH)		(Present for notes 1–10)
Justin Davies (JD)		(Present for notes 1–10)
Gemma Burgess (GB)		(Present for notes 1–7)
Julie Hepburn (JH)		(Present for notes 1–10)
Debby Lennard (DL)		(Present for notes 1–10)
Kevin Monahan (KM)		(Present for notes 1–10)
Charlotte Dawson (CD)		(Present for notes 1–10)
Michael Braun (MB)		(Present for notes 1–10)

In attendance:		
Gareth Haman	NICE Senior Medical Editor	(Present for notes 1–10)
Adam Storrow	NICE Resource Impact Lead	(Present for notes 1–8)
Matthew Prettyjohns (MP)	NGA Guideline Lead	(Present for notes 1–10)
Michaela Dijmarescu (MD)	NGA Project Manager	(Present for notes 1–10)
Maija Kalioinen (MK)	NGA Systematic Reviewer	(Present for notes 1–10)
Nathan Bromham (NB)	NGA Senior Systematic Reviewer	(Present for notes 1–10)
Audrey Tan (AT) <i>via VC</i>	NGA Systematic Reviewer	(Present for notes 7–10)
Agnesa Mehmeti (AM)	NGA Information Scientist	(Present for notes 1–10)

Observers:	
None	

4.0.03 DOC Cmte minutes

Apologies:	
Baljit Singh (BS)	Committee Member
Jay Bradbury (JB)	Committee Member
Vivek Misra (VM)	Committee Member
Richard Roope (RR)	Committee Member

1. Welcome and objectives for the meeting

The Chair welcomed the committee members to the third meeting for the colorectal cancer (CRC) guideline update.

The Chair informed the Committee that apologies had been received as noted above.

The Chair outlined the objectives of the meeting, which included:

- Presentations from the NICE Resource Impact Lead and the NICE Senior Medical Editor for the guideline;
- Developing 4 protocols for review questions 3.7, 4.1, 4.3 and 5.1;

The minutes of the second colorectal cancer guideline committee meeting were confirmed with the Committee.

The Chair led round the table introductions for the group. A new committee member joined the group (Michael Braun).

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was colorectal cancer.

The Chair asked everyone to verbally declare any interests.

There was one declarations of interest included in the table below.

Name	Job title, organisation	Declarations of Interest	Type of interest	Decision taken
-------------	--------------------------------	---------------------------------	-------------------------	-----------------------

4.0.03 DOC Cmte minutes

Kevin Monahan	Gastroenterologist, Chelsea & Westminster Hospitals NHS Trust, London	Response to letter to editor regarding published article – metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis. Lythgoe, M.P., Malik, S.S., McPhail, M. & Monahan, K.J. [18.02.2018]	Personal non-financial, specific	Declare and participate
2. NICE Resource Impact presentation				
The Chair introduced Adam Storrow (NICE Resource Impact Lead) who presented the NICE Resource Impact team aims and role in developing the guideline.				
3. Economic Priorities presentation				
The Chair introduced Matthew Prettyjohns (NGA Guideline Lead/ Senior Health Economist) who presented and discussed with the committee the guideline economic priorities.				
4. Develop protocol for review question 3.7 What is the optimal duration of adjuvant chemotherapy for colorectal cancer?				
The Chair introduced Maija Kailionen (NGA Systematic Reviewer) who presented the protocol for review question 3.7 and finalised it with the Committee.				
5. NICE Editor presentation				
The Chair introduced Gareth Haman (NICE Senior Medical Editor) who presented to the Committee the work done by the NICE editorial team and the role of the editor in guideline development.				
6. Develop protocols for review 4.1 What is the most effective first-line chemotherapy for people with metastatic colorectal cancer (RASmutant)?				
The Chair introduced Nathan Bromhan (NGA Senior Systematic Reviewer) who presented the protocols for review question 4.1 and finalised it with the Committee.				
7. Develop protocols for review questions 4.3: a. What is the optimal combination and sequence of local and systemic treatments in patients presenting with oligometastatic colorectal cancer in the lung? b. What is the optimal combination and sequence of local, loco-regional and systemic				

4.0.03 DOC Cmte minutes

treatments in patients presenting with oligometastatic colorectal cancer in the liver?

c. What is the optimal combination and sequence of local and systemic treatments in patients presenting with isolated metastatic colorectal cancer in the peritoneum?

The Chair introduced Nathan Bromham (NGA Senior Systematic Reviewer) and Audrey Tan (NGA Systematic Reviewer – *joining the meeting via VC*) who presented the protocols for review question 4.3 and finalised them with the committee.

8. Develop protocols for review 5.1 What are the optimal methods and frequencies of follow-up after potentially curative surgical treatment for colorectal cancer (primary or metastatic)?

The Chair introduced Nathan Bromham (NGA Senior Systematic Reviewer) who presented the protocol for review question 5.1 and finalised it with the committee.

9. Any other business

Matthew Prettyjohns (NGA Guideline Lead/ Senior Health Economist) updated the committee with regards to the submitted development time request and timelines.

10. Close of meeting

The Chair reminded the Committee that the next meeting would be held on the 29th March 2018 at the RCOG, London and closed the third guideline committee meeting for the NICE Colorectal Cancer (update) guideline.

Date of next meeting: 29th March 2018

Location of next meeting: RCOG, London